Harold Bays, MD
Enriched profileMedical Director and President, Louisville Metabolic and Atherosclerosis Research Center (L-MARC) · Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
Harold Bays is Medical Director and President, Louisville Metabolic and Atherosclerosis Research Center (L-MARC) at Louisville Metabolic and Atherosclerosis Research Center (L-MARC). OpenAlex indexes 501 publications with 32,856 citations (h-index 87); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.
Data verified 17 Aug 2026
Overview
Updated 27 Aug 2026
Harold Bays, MD, is Medical Director and President, Louisville Metabolic and Atherosclerosis Research Center (L-MARC). The public record shows 501 publications with 32,856 citations (h-index 87), centered on Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Pharmacology and Obesity Treatment. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 14 companies.
- Most recent indexed publication: 2026 · Journal of medical economics
- Top research focus: Lipoproteins and Cardiovascular Health
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 14 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 261.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- Co-author/advocate
"Obesity and Advocacy: A Joint Clinical Perspective and Expert Review from the Obesity Medicine Association and the Obesity Action Coalition" (2024): supports the Treat and Reduce Obesity Act (TROA) …
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pmc.ncbi.nlm.nih.gov ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Sponsor: Eli Lilly and Company
Industry payments
Updated 27 Aug 2026
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202524 payments$22,080openpaymentsdata.cms.gov ↗
- Eli Lilly and CompanyProgram year202513 payments$11,332openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year202510 payments
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
4 congress contributions (2005–2020) across AACE, ADA per OpenAlex. The most recent:
- Efficacy and Safety of Evolocumab in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia or Mixed Dyslipidemia
ADA Scientific Sessions
ADA2018Co-author - Improved Cardiovascular and Renal Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program Irrespective of Baseline (BL) Body Mass Index (BMI)
ADA Scientific Sessions
ADA2018Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economics
Clinical Trial2026 - Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.
Obesity (Silver Spring, Md.)
Article2026 - Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.
Obesity (Silver Spring, Md.)
Clinical Trial2026 - Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4.
Obesity (Silver Spring, Md.)
Clinical Trial2025 - Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN.
Obesity (Silver Spring, Md.)
Article2025
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant PatientsArticle914 citations2023
- 04Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight ManagementArticle912 citations2010
- 05Safety and Efficacy of Bempedoic Acid to Reduce LDL CholesterolArticle804 citations2019
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obesitymedicine.org ↗
- Board Certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obesitymedicine.org ↗ - Board Certified
Endocrinology, Diabetes and Metabolism
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obesitymedicine.org ↗ - Diplomate
American Board of Obesity Medicine (DABOM)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obesitymedicine.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →reachmd.com ↗
- Chairman
2010 American Association of Clinical Endocrinologists Adipose Tissue Pathophysiology State of the Science Conference
2010provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →reachmd.com ↗ - Chief Science Officer
Obesity Medicine Association
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obesitymedicine.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obesitymedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obesitymedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obesitymedicine.org ↗
Secondary affiliations
appointments beyond the home institution- Clinical Associate Professor
University of Louisville School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obesitymedicine.org ↗
Media & interviews
press, podcasts and appearances- Video interview
"Harold Bays, MD: A Different World for Obesity Treatment", HCPLive
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com ↗ - Video interview
"Harold Bays, MD: Considering the Future of Anti-Obesity Medications", HCPLive
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council